R&D Spending and Its Distortion of Healthcare Financials

Introduction

One of the first things healthcare bankers learn is that reported financials in healthcare are not directly comparable to other sectors, and often not even comparable across healthcare sub-sectors. The primary culprit is R&D expense treatment under GAAP. US accounting rules require that all research and development spending be expensed in the period incurred, regardless of whether that spending will generate future revenue. For a company spending $50 million on a Phase III trial that could produce a $2 billion per year drug, the entire $50 million hits the income statement as an operating expense in the current year.

This treatment creates two significant analytical distortions that healthcare bankers encounter daily.

Distortion 1: Artificially Depressed Margins for R&D-Intensive Companies

Big Pharma companies spend 15-25% of revenue on R&D. Merck spent approximately $16 billion on R&D in 2024 (roughly 26% of revenue). Roche spent over $14 billion (roughly 22%). These are investments in future products that may not generate revenue for 5-10 years, but they reduce current-period EBITDA as if they were ordinary operating expenses.

R&D Intensity

The ratio of R&D spending to total revenue, expressed as a percentage. Pharma companies typically operate at 15-25% R&D intensity, biotech companies at 50-200%+ (often exceeding revenue entirely), medtech companies at 5-10%, and healthcare services companies at near-zero. This variation makes cross-sector EBITDA margin comparisons meaningless without adjustment.

When you see a pharma company with a 30% EBITDA margin and an industrial company with a 30% EBITDA margin, these numbers are not equivalent. The pharma company is spending 20% of revenue on investments that will generate returns over the next decade, while the industrial company's 3-5% R&D spend is closer to a true maintenance cost. If you capitalized and amortized the pharma company's R&D over a 10-year useful life, its adjusted EBITDA margin would be significantly higher.

Distortion 2: Inverted Financials for Clinical-Stage Biotechs

For pre-revenue biotech companies, the R&D distortion is extreme. A clinical-stage biotech with a promising Phase III pipeline might spend $150-300 million per year on R&D with zero product revenue. Under GAAP, this company reports massive operating losses, negative EBITDA, and negative net income. Its financial statements look like a failing business, when in reality it may be creating significant value through pipeline development.

This is why standard financial metrics are useless for clinical-stage biotechs. You cannot calculate meaningful EBITDA margins, P/E ratios, or return on equity. The company's entire value is in its pipeline, and rNPV is the only appropriate valuation methodology because it values the expected future cash flows from pipeline assets rather than current (nonexistent) earnings.

An additional complication arises from differences between US GAAP and International Financial Reporting Standards (IFRS). Under IFRS (IAS 38), companies can capitalize development costs once certain criteria are met (technical feasibility, intention to complete, ability to use or sell, probable future economic benefits, and ability to measure costs reliably). Under US GAAP (ASC 730), virtually all R&D must be expensed immediately.

This means European pharma companies reporting under IFRS (Roche, Novartis, Sanofi, AstraZeneca, GSK) may capitalize certain development costs, while US pharma companies (Pfizer, Merck, J&J, AbbVie, Lilly) expense everything. When building comparable company analyses that include both US and European peers, healthcare bankers must normalize for this difference to ensure apples-to-apples comparison.

Understanding R&D distortion is a foundational skill that affects every healthcare valuation. It explains why standard multiples need context, why biotech financial statements should not be interpreted at face value, and why healthcare bankers develop a more nuanced relationship with reported financials than bankers in most other coverage groups.